AL-ADTRAN
5.12.2023 14:01:36 CET | Business Wire | Press release
Adtran today celebrated adding over 300 new Mosaic One customers in under 18 months. The rapid adoption of Adtran’s cloud-based software-as-a-service (SaaS) platform highlights its ability to address the demands of modern broadband networks. Mosaic One optimizes network operations by utilizing advanced AI-driven algorithms to anticipate and resolve issues before they impact performance. Its three dedicated portals - Care, Operate and Promote – enable service providers to manage complex deployments, reduce costs and deliver superior services to their subscribers. What’s more, Mosaic One is vendor- and technology-neutral, providing an all-encompassing monitoring solution for FTTH, DOCSIS, DSL and fixed wireless networks across multiple vendors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231205627594/en/
Adtran’s Mosaic One helps service providers maximize the value of their fiber networks. (Photo: Business Wire)
“DFN’s partnership with Adtran and Mosaic One delivers real-time data and insights for our network and customer service teams, allowing us to care for our customers and fiber network proactively and efficiently,” said Todd Way, CEO of DFN. “The Mosaic Marketing Center has also been a considerable time and cost saver for DFN. Our marketing manager can quickly execute and customize community-centered campaigns with the click of a few buttons. Mosaic One positively impacts our operations, our employees and our customers.”
Mosaic One is a vendor- and technology-agnostic solution designed to adapt to the evolving needs of both service providers and end-users. With its predictive insights, real-time monitoring and intuitive user interface, it provides new opportunities and alleviates the workload for support teams, network engineers and marketers. It’s also recently been enhanced with several new features and capabilities. These include Intellifi®, Adtran’s cloud-managed Wi-Fi solution. This provides service providers with unprecedented control over the home Wi-Fi experience, maximizing customer satisfaction, loyalty and spend.
Additionally, the newly introduced Mosaic Marketing Center is a comprehensive marketing platform, offering professionally produced promotional materials, including videos, animated explainers and local stock photography to amplify campaigns. It features an instant customization tool, enabling swift branding and deployment of content, ensuring service providers can quickly tailor and launch their marketing initiatives. Also integrated into the platform is the Fiber Gaming Network, a fully managed turnkey solution for esports management, presenting fresh avenues for revenue growth.
“In less than 18 months, Mosaic One has hit a huge milestone. We often talk about how it empowers service providers to maximize the value of fiber networks. But Mosaic One’s success is also due to the fact that it gives customers what they need — a service with no hidden fees and no additional charges post-deployment. Many of our new customers came to us drained by the intricate licensing and perplexing invoicing their prior vendors used. Instead, what you get with Mosaic One is one invoice, one service, one incredibly easy way to manage your entire network,” commented Robert Conger, GM of software platforms at Adtran. “Achieving 300 deployments in such a short period is impressive, but for Mosaic One, it’s just the beginning. With more service-enhancing and revenue-boosting features in the pipeline, we’ll help shape a new era of opportunity for service providers.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231205627594/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
